As of close of business last night, Biogen Inc’s stock clocked out at $207.64, down -3.35% from its previous closing price of $214.83. In other words, the price has decreased by -$7.19 from its previous closing price. On the day, 1462202 shares were traded.
Ratios:
To gain a deeper understanding of BIIB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.26 and its Current Ratio is at 2.00. In the meantime, Its Debt-to-Equity ratio is 0.50 whereas as Long-Term Debt/Eq ratio is at 0.49.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on February 14, 2024, Reiterated its Buy rating but revised its target price to $300 from $305 previously.
On February 14, 2024, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $315 to $240.
UBS Downgraded its Buy to Neutral on January 24, 2024, whereas the target price for the stock was revised from $311 to $276.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 22 ’24 when Singhal Priya sold 262 shares for $221.23 per share. The transaction valued at 57,962 led to the insider holds 4,886 shares of the business.
Singhal Priya sold 108 shares of BIIB for $23,921 on Feb 16 ’24. The Head of Development now owns 5,148 shares after completing the transaction at $221.49 per share. On Feb 15 ’24, another insider, Rowinsky Eric K, who serves as the Director of the company, bought 455 shares for $222.54 each. As a result, the insider paid 101,256 and bolstered with 20,629 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIIB now has a Market Capitalization of 30.18B and an Enterprise Value of 36.47B. As of this moment, Biogen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.02, and their Forward P/E ratio for the next fiscal year is 11.75. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 9.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.21 while its Price-to-Book (P/B) ratio in mrq is 2.03. Its current Enterprise Value per Revenue stands at 3.71 whereas that against EBITDA is 17.89.
Stock Price History:
Over the past 52 weeks, BIIB has reached a high of $319.76, while it has fallen to a 52-week low of $211.01. The 50-Day Moving Average of the stock is 228.15, while the 200-Day Moving Average is calculated to be 251.05.
Shares Statistics:
It appears that BIIB traded 1.18M shares on average per day over the past three months and 1.23M shares per day over the past ten days. A total of 144.90M shares are outstanding, with a floating share count of 144.19M. Insiders hold about 0.80% of the company’s shares, while institutions hold 90.17% stake in the company. Shares short for BIIB as of Mar 15, 2024 were 2.66M with a Short Ratio of 2.26, compared to 3.1M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.83% and a Short% of Float of 2.06%.
Earnings Estimates
As of right now, 26 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $3.49 for the current quarter, with a high estimate of $4.57 and a low estimate of $3.04, while EPS last year was $3.4. The consensus estimate for the next quarter is $3.94, with high estimates of $6.14 and low estimates of $3.25.
Analysts are recommending an EPS of between $16.08 and $14.83 for the fiscal current year, implying an average EPS of $15.48. EPS for the following year is $17.62, with 30 analysts recommending between $21.39 and $12.33.
Revenue Estimates
In the current quarter, 23 analysts expect revenue to total $2.32B. It ranges from a high estimate of $2.44B to a low estimate of $2.24B. As of the current estimate, Biogen Inc’s year-ago sales were $2.34B, an estimated decrease of -1.00% from the year-ago figure. For the next quarter, 23 analysts are estimating revenue of $2.38B, an increase of 0.50% over than the figure of -$1.00% in the same quarter last year. There is a high estimate of $2.43B for the next quarter, whereas the lowest estimate is $2.32B.
A total of 31 analysts have provided revenue estimates for BIIB’s current fiscal year. The highest revenue estimate was $9.76B, while the lowest revenue estimate was $9.17B, resulting in an average revenue estimate of $9.48B. In the same quarter a year ago, actual revenue was $9.84B, down -3.60% from the average estimate. Based on 31 analysts’ estimates, the company’s revenue will be $9.61B in the next fiscal year. The high estimate is $11.45B and the low estimate is $8.42B. The average revenue growth estimate for next year is up 1.40% from the average revenue estimate for this year.
